Expression of stress-induced phosphoprotein1 (STIP1) is associated with tumor progression and poor prognosis in epithelial ovarian cancer

Hanbyoul Cho, Sunghoon Kim, Ha Yeon Shin, Eun Joo Chung, Haruhisa Kitano, Jae Hyon Park, Lucienne Park, Joon Yong Chung, Stephen M. Hewitt, Jae-Hoon Kim

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Stress-induced phosphoprotein1 (STIP1) is a candidate biomarker in epithelial ovarian cancer (EOC). In this study, we investigated in detail the expression of STIP1, as well as its functions, in EOC. STIP1 expression was assessed by immunohistochemistry (IHC) and the results were compared with clinicopathologic factors, including survival data. The effects of STIP1 gene silencing via small interfering RNA (siRNA) were examined in EOC cells and a xenograft model. The expression of STIP1 protein in EOC was significantly higher than in the other study groups (P<0.001), and this increase of expression was significantly associated with tumor stage (P=0.005), tumor grade (P=0.029), and lymph node metastasis (P=0.020). In multivariate analysis, overall survival in EOC was significantly shorter in cases with high STIP1 expression (HR=2.78 [1.01-7.63], P=0.047). STIP1 silencing in EOC cells resulted in inhibition of cell proliferation and invasion. In addition, in vivo experiments using STIP1 siRNA clearly showed a strong inhibition of tumor growth and a modulation of expression of prosurvival and apoptotic genes, further suggesting that STIP1 silencing can prevent cell proliferation and invasion. In conclusion, increased STIP1 expression is associated with poor survival outcome in EOC, and STIP1 may represent a useful therapeutic target in EOC patients.

Original languageEnglish
Pages (from-to)277-288
Number of pages12
JournalGenes Chromosomes and Cancer
Volume53
Issue number4
DOIs
Publication statusPublished - 2014 Apr 1

Fingerprint

Neoplasms
Small Interfering RNA
Survival
Cell Proliferation
Ovarian epithelial cancer
Gene Silencing
Heterografts
Multivariate Analysis
Biomarkers
Lymph Nodes
Immunohistochemistry
Neoplasm Metastasis
Growth
Genes
Proteins
Therapeutics

All Science Journal Classification (ASJC) codes

  • Genetics
  • Cancer Research

Cite this

Cho, Hanbyoul ; Kim, Sunghoon ; Shin, Ha Yeon ; Chung, Eun Joo ; Kitano, Haruhisa ; Hyon Park, Jae ; Park, Lucienne ; Chung, Joon Yong ; Hewitt, Stephen M. ; Kim, Jae-Hoon. / Expression of stress-induced phosphoprotein1 (STIP1) is associated with tumor progression and poor prognosis in epithelial ovarian cancer. In: Genes Chromosomes and Cancer. 2014 ; Vol. 53, No. 4. pp. 277-288.
@article{241f54ebb15744ac9f9589965b74ef67,
title = "Expression of stress-induced phosphoprotein1 (STIP1) is associated with tumor progression and poor prognosis in epithelial ovarian cancer",
abstract = "Stress-induced phosphoprotein1 (STIP1) is a candidate biomarker in epithelial ovarian cancer (EOC). In this study, we investigated in detail the expression of STIP1, as well as its functions, in EOC. STIP1 expression was assessed by immunohistochemistry (IHC) and the results were compared with clinicopathologic factors, including survival data. The effects of STIP1 gene silencing via small interfering RNA (siRNA) were examined in EOC cells and a xenograft model. The expression of STIP1 protein in EOC was significantly higher than in the other study groups (P<0.001), and this increase of expression was significantly associated with tumor stage (P=0.005), tumor grade (P=0.029), and lymph node metastasis (P=0.020). In multivariate analysis, overall survival in EOC was significantly shorter in cases with high STIP1 expression (HR=2.78 [1.01-7.63], P=0.047). STIP1 silencing in EOC cells resulted in inhibition of cell proliferation and invasion. In addition, in vivo experiments using STIP1 siRNA clearly showed a strong inhibition of tumor growth and a modulation of expression of prosurvival and apoptotic genes, further suggesting that STIP1 silencing can prevent cell proliferation and invasion. In conclusion, increased STIP1 expression is associated with poor survival outcome in EOC, and STIP1 may represent a useful therapeutic target in EOC patients.",
author = "Hanbyoul Cho and Sunghoon Kim and Shin, {Ha Yeon} and Chung, {Eun Joo} and Haruhisa Kitano and {Hyon Park}, Jae and Lucienne Park and Chung, {Joon Yong} and Hewitt, {Stephen M.} and Jae-Hoon Kim",
year = "2014",
month = "4",
day = "1",
doi = "10.1002/gcc.22136",
language = "English",
volume = "53",
pages = "277--288",
journal = "Genes Chromosomes and Cancer",
issn = "1045-2257",
publisher = "Wiley-Liss Inc.",
number = "4",

}

Expression of stress-induced phosphoprotein1 (STIP1) is associated with tumor progression and poor prognosis in epithelial ovarian cancer. / Cho, Hanbyoul; Kim, Sunghoon; Shin, Ha Yeon; Chung, Eun Joo; Kitano, Haruhisa; Hyon Park, Jae; Park, Lucienne; Chung, Joon Yong; Hewitt, Stephen M.; Kim, Jae-Hoon.

In: Genes Chromosomes and Cancer, Vol. 53, No. 4, 01.04.2014, p. 277-288.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Expression of stress-induced phosphoprotein1 (STIP1) is associated with tumor progression and poor prognosis in epithelial ovarian cancer

AU - Cho, Hanbyoul

AU - Kim, Sunghoon

AU - Shin, Ha Yeon

AU - Chung, Eun Joo

AU - Kitano, Haruhisa

AU - Hyon Park, Jae

AU - Park, Lucienne

AU - Chung, Joon Yong

AU - Hewitt, Stephen M.

AU - Kim, Jae-Hoon

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Stress-induced phosphoprotein1 (STIP1) is a candidate biomarker in epithelial ovarian cancer (EOC). In this study, we investigated in detail the expression of STIP1, as well as its functions, in EOC. STIP1 expression was assessed by immunohistochemistry (IHC) and the results were compared with clinicopathologic factors, including survival data. The effects of STIP1 gene silencing via small interfering RNA (siRNA) were examined in EOC cells and a xenograft model. The expression of STIP1 protein in EOC was significantly higher than in the other study groups (P<0.001), and this increase of expression was significantly associated with tumor stage (P=0.005), tumor grade (P=0.029), and lymph node metastasis (P=0.020). In multivariate analysis, overall survival in EOC was significantly shorter in cases with high STIP1 expression (HR=2.78 [1.01-7.63], P=0.047). STIP1 silencing in EOC cells resulted in inhibition of cell proliferation and invasion. In addition, in vivo experiments using STIP1 siRNA clearly showed a strong inhibition of tumor growth and a modulation of expression of prosurvival and apoptotic genes, further suggesting that STIP1 silencing can prevent cell proliferation and invasion. In conclusion, increased STIP1 expression is associated with poor survival outcome in EOC, and STIP1 may represent a useful therapeutic target in EOC patients.

AB - Stress-induced phosphoprotein1 (STIP1) is a candidate biomarker in epithelial ovarian cancer (EOC). In this study, we investigated in detail the expression of STIP1, as well as its functions, in EOC. STIP1 expression was assessed by immunohistochemistry (IHC) and the results were compared with clinicopathologic factors, including survival data. The effects of STIP1 gene silencing via small interfering RNA (siRNA) were examined in EOC cells and a xenograft model. The expression of STIP1 protein in EOC was significantly higher than in the other study groups (P<0.001), and this increase of expression was significantly associated with tumor stage (P=0.005), tumor grade (P=0.029), and lymph node metastasis (P=0.020). In multivariate analysis, overall survival in EOC was significantly shorter in cases with high STIP1 expression (HR=2.78 [1.01-7.63], P=0.047). STIP1 silencing in EOC cells resulted in inhibition of cell proliferation and invasion. In addition, in vivo experiments using STIP1 siRNA clearly showed a strong inhibition of tumor growth and a modulation of expression of prosurvival and apoptotic genes, further suggesting that STIP1 silencing can prevent cell proliferation and invasion. In conclusion, increased STIP1 expression is associated with poor survival outcome in EOC, and STIP1 may represent a useful therapeutic target in EOC patients.

UR - http://www.scopus.com/inward/record.url?scp=84894054476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894054476&partnerID=8YFLogxK

U2 - 10.1002/gcc.22136

DO - 10.1002/gcc.22136

M3 - Article

VL - 53

SP - 277

EP - 288

JO - Genes Chromosomes and Cancer

JF - Genes Chromosomes and Cancer

SN - 1045-2257

IS - 4

ER -